This is a big week for our friends on the west coast as Dexcom (NASDAQ: DXCM), MannKind (NASDAQ: MNKD) and Tandem (NASDAQ: TNDM) all report fourth quarter and full year results. Of the three we will be paying very close attention to what Tandem has to say, although we were somewhat surprised that Dexcom according to recent SEC filings now owns 2.5 million shares of Tandem. This really isn’t a surprise given the way things have been going with the company’s insulin pump partners. The last thing Dexcom wants is another Animas situation.
Now before everyone starts . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.